Clinical Trial Update: Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

Phase 2 retreatment trial of BL22 immunotherapy in patients with relapsed or refractory Hairy Cell Leukemia was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• BL22 immunotherapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2012-05-01